Valeant Pharma (VRX) to Employ Drug Discounting Strategy in Effort to 'Protect Volume'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- S&P Dow Jones Indices adds Bloom Energy to S&P 500 index
- Citi highlights best Gen AI stocks to own for 2027
- Dell’s earning report was bullish for Intel CPU demand, analyst says
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- Netflix raises prices in Germany and Austria, Citi comments
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
UPDATE: Eventually Valeant (VRX) Fundamentals Will Matter Again - UBS
November 11, 2015 9:44 AM EST(Updated - November 11, 2015 9:49 AM EST)
(correction: price target is $255)
UBS analyst Marc Goodman reiterated a Buy rating and $255 price target on Valeant Pharmaceuticals (NYSE: VRX) following yesterday's business update. The analyst said eventually fundamentals will matter again. Goodman listed 6 takeaways from... More
Valeant (VRX) 'Conservative Base Case' Suggests 109% Upside - Nomura
November 11, 2015 7:20 AM ESTNomura Securities analyst Shibani Malhotra lowered her price target on Valeant Pharmaceuticals (NYSE: VRX) to $175.00 (from $220.00) but reiterated a Buy rating as her "Conservative Base Case" suggest 109% upside to current levels.
While the call did not address all our outstanding questions; however,... More
JPMorgan Cuts PT on Valeant (VRX) to $225
November 11, 2015 6:42 AM ESTJPMorgan trims its price target on Valeant Pharma (NYSE: VRX) from $265 down to $225. The firm maintained its Overweight rating on Valeant
For an analyst ratings summary and ratings history on Valeant Pharmaceuticals click here. For more ratings news on Valeant Pharmaceuticals click here.
... MorePhilidor Rx Disappointed Relationship with Valeant (VRX) Has Ended
November 10, 2015 5:22 PM ESTPhilidor Rx said in a statement:
We have valued our close working relationship with Valeant (NYSE: VRX) and are deeply disappointed that is has come to an end. It is unfortunate that this outcome was influenced by market forces, media misperceptions, and inflammatory,... More
Valeant Pharma (VRX) CEO Pearson Says Company 'is Going to Survive'
November 10, 2015 9:25 AM ESTWith its conference call today, Valeant Pharma (NYSE: VRX) said it doesn't have contingency plans if the stock keeps falling and it will sustain a short-term hit in its dermatology business.
CEO Michael Pearson also the company "is going to survive" and... More
UPDATE: Valeant Pharma (VRX) Sees Negative Q4 Impact from Recent Events; Will Issue New Guidance in Dec.
November 10, 2015 8:08 AM EST(Updated - November 10, 2015 8:23 AM EST)
(Updated - November 10, 2015 8:17 AM EST)
Valeant Pharma (NYSE: VRX) sees negative impact on dermatology in Q4, according to the company's... More
